Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies

Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies

Nizar Jacques Bahlis, Associate Professor of Medicine at the University of Calgary, posted on X:

“SMM: Taking the narrow over the wide path. This is a plea (and not a criticism) to the myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM (Smoldering multiple myeloma) as MGUS or MM.”

Read Further.
Source: Nizar Jacques Bahlis/ X

biomarkers studies cancer immunogenomic MGUS MM multiple myeloma Myeloma OncoDaily Oncology SMM Smoldering multiple myeloma